SCHEMBL6768892

SCHEMBL6768892

CCC(C)NCc1c(C(=O)O)nn(-c2ccccc2Cl)c1Oc1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 13/20 0.43
KMT2A Q03164 1/20 0.41
PDE4B Q07343 2/20 0.40
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6769130 0.93 PDE4B (0.46) CNR1KMT2APDE4BKDM4EMAPT
SCHEMBL6776610 0.92 CNR1 (0.42) CNR1KMT2APDE4BKDM4EMAPT
SCHEMBL6770283 0.92 CNR1 (0.49) CNR1
SCHEMBL6765945 0.92 CNR1 (0.49) CNR1
SCHEMBL6769413 0.91 CNR1 (0.44) CNR1
SCHEMBL6766475 0.90 CNR1 (0.49) CNR1
SCHEMBL6771394 0.89 CNR2 (0.45) CNR1
SCHEMBL6770289 0.89 CNR2 (0.43) CNR1
SCHEMBL6775297 0.89 CNR1 (0.46) CNR1
SCHEMBL6770159 0.88 CNR2 (0.45) CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-11-25 US claimed
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 CNR1 1/4885KMT2A 3731/4885PDE4B 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.